Establishing a successful outpatient CAR T-cell program with cilta-cel: Real-world experience from an expert roundtable

Last Updated: Friday, October 10, 2025

A panel of hematology/oncology specialists with expertise in myeloma and cellular therapies convened a roundtable discussion to highlight the practical aspects of cilta-cel outpatient programs. They shared real-world experiences, offering insights on feasibility, safety, and effectiveness, and identified key success factors to help institutions, patients, and caregivers prepare for similar initiatives.

Future Oncology

Establishing a successful outpatient CAR T-cell program with cilta-cel: Real-world experience from an expert roundtable

Blood

Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy

EBioMedicine

Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment

Diagnostics (Basel)

CAR-T cell therapy in ovarian cancer: Where are we now?

U.S. Food and Drug Administration

FDA eliminates risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor CAR T-cell immunotherapies

Journal for ImmunoTherapy of Cancer

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR T-cell therapy in solid tumors

Nature Reviews Immunology

In vivo CAR engineering for immunotherapy

Seminars in Arthritis and Rheumatism

Advancing autoimmune rheumatic disease treatment: CAR T-cell therapies—evidence, safety, and future directions

Blood Advances

BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement

Blood Advances

Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: A SEER-Medicare data analysis

CAR T-Cell Therapy Resource Center

Establishing a successful outpatient CAR T-cell program with cilta-cel: Real-world experience from an expert roundtable

Future Oncology

Establishing a successful outpatient CAR T-cell program with cilta-cel: Real-world experience from an expert roundtable

Blood

Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy

EBioMedicine

Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment

Diagnostics (Basel)

CAR-T cell therapy in ovarian cancer: Where are we now?

U.S. Food and Drug Administration

FDA eliminates risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor CAR T-cell immunotherapies

Journal for ImmunoTherapy of Cancer

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR T-cell therapy in solid tumors

Nature Reviews Immunology

In vivo CAR engineering for immunotherapy

Seminars in Arthritis and Rheumatism

Advancing autoimmune rheumatic disease treatment: CAR T-cell therapies—evidence, safety, and future directions

Blood Advances

BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement

Blood Advances

Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: A SEER-Medicare data analysis

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

Fast Facts #12: BCMA Targets